2025 ASGCT | Immunofoco's In Vivo CAR-T Technology Platform Debuts with Groundbreaking Innovations
MxV-G is a novel fusogen for lentiviral packaging that achieves higher vector titers and enhanced transduction efficiency. The detargeted MxV-G mutant abolishes native receptor binding while preserving its fusogenic activity. With various TCMs, the...
Avance Clinical Honored with Frost & Sullivan's 2025 Global Customer Value Leadership Award for Transformative Biotech CRO Services
This award recognizes Avance Clinical's strategic innovation, operational agility, and unwavering commitment to client success in early-phase clinical trials. SAN ANTONIO, May 14, 2025 /PRNewswire/ -- Frost & Sullivan has named Avance Clinical...
iNtRON Seeks a Strategic Partner to Explore the Promising Market for MRSA Decolonization
Aiming to Provide a Novel Solution Against Post-Operative MRSA Infections Demonstrated its Efficacy and Safety through previous Clinical Trials Company seeks global partners to co-develop toward Commercialization SEOUL, South Korea and BOSTON, May...
Hyundai ADM Bio Voluntarily Withdraws IND for Clinical Study of Docetaxel Combination Cancer Therapy to Focus on Immunotherapy Strategy
Declares a strategic pivot to lead the post-patent immunotherapy combination era SEOUL, South Korea, May 13, 2025 /PRNewswire/ -- Hyundai ADM Bio (KOSDAQ symbol 187660) today announced the voluntary withdrawal of its Investigational New Drug (IND)...
Care Begins Within Because Ingredients Matter: Lenzing's VEOCEL™ Champions Sustainable Innovation at IDEA25 and CIDPEX
VEOCEL™ highlighted its innovative, environmentally responsible fibers for hygiene and personal care single-use products at CIDPEX and IDEA25 With VEOCEL™ Lyocell, Lenzing invites partners to unleash possibilities in single-use – not only meeting...
Telix FAP-targeting Therapeutic Published in Thyroid Journal: Demonstrates Encouraging Efficacy
MELBOURNE, Australia and INDIANAPOLIS, May 8, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces that its Fibroblast Activation Protein (FAP)-targeting therapy candidate, TLX400, has been...
NetDragon Participates in Digital China Summit for the 8th Consecutive Year, Pioneering AI-Driven Innovation in Gaming and Education
HONG KONG, May 7, 2025 /PRNewswire/ -- NetDragon Websoft Holdings Limited ("NetDragon" or the "Company"; Hong Kong Stock Code: 0777), a global leader in building internet communities, is pleased to announce its participation in the 8th Digital China...
Ascletis Announces Oral and Poster Presentations on ASC47, an Adipose-Targeted, Muscle-Preserving Weight Loss Drug Candidate for Obesity at the 32nd European Congress on Obesity
HONG KONG, May 6, 2025 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX:1672, "Ascletis") announces oral and poster presentations on preliminary studies of ASC47, an adipose-targeted, muscle-preserving weight loss drug candidate for obesity, will be...
Gamma Communications Recognized with Frost & Sullivan's 2024 European UCaaS Competitive Strategy Leadership Award
The company has shown exceptional strategy execution, innovation, and customer-centric growth in a rapidly evolving market. SAN ANTONIO, Texas, May 6, 2025 /PRNewswire/ -- Frost & Sullivan is proud to present Gamma Communications with the 2024...
IND Application for NTS071, Nutshell Therapeutics' p53 Y220C Allosteric Reactivator, Received US FDA clearance
SHANGHAI, May 4, 2025 /PRNewswire/ -- On April 23, 2025, Nutshell Therapeutics ( Shanghai ) Co., LTD. received IND clearance from the FDA to initiate P hase 1 clinical trial in the United States for its NTS071, a novel small molecule allosteric...